Barry Greene, Sage CEO
Ahead of FDA filing, Sage and Biogen tout more data in hopes of alleviating durability concerns
With an FDA filing rolling for zuranolone, Sage and Biogen are bringing more data on how the drug works in an open-label study.
The partners …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
